Despite high demand, a severe shortage of suitable allografts limits the use of liver transplantation for the treatment of end-stage liver disease. The transplant community is turning to the utilization of high-risk grafts to fill the void. This review summarizes the reemergence of ex-vivo machine perfusion for liver graft preservation, including results of recent clinical trials and its specific role for reconditioning DCD, steatotic and elderly grafts.
INTRODUCTION
The concept of ex-vivo machine perfusion dates at least back to the Lindbergh Apparatus in the 1930s, establishing prolonged ex-vivo metabolic function in isolated organs [1, 2] . Belzer et al. [3] first applied machine perfusion to human transplantation with the successful transplantation a kidney following 17 h of hypothermic machine perfusion (HMP); Starzl et al. [4] subsequently transplanted 7 HMPpreserved livers.
The development of specialized preservation solutions in the 1980s allowed static cold storage (SCS) to emerge as the primary organ preservation modality, shelving the need for machine perfusion [5] . SCS was a simple, effective and transportable alternative to the cumbersome machine perfusion devices of the time. Organ preservation with SCS has been remarkably successful over the past 30 years, facilitating widespread application of liver transplantation as the only treatment for end-stage liver disease.
Global trends in liver disease combined with the success of liver transplantation have increased demand for transplantation, resulting in a shortage of suitable organs. One strategy to expand the donor pool is utilization of extended criteria donor (ECD) grafts, specifically donation after circulatory death (DCD), steatotic or elderly grafts. These marginal organs have increased susceptibility to ischemia reperfusion injury (IRI) and subsequent high risk of primary nonfunction (PNF), early allograft dysfunction (EAD) and biliary complications. These risks demand strict limitations on allowable ischemia time and minimization of other risk factors, precluding routine use of ECD grafts [6] .
Utilizing ECD grafts depends on optimizing preservation conditions. Metabolic activity during SCS is substantially slowed, but does not cease completely. Oxygen debt results in deranged mitochondrial metabolism and accumulation of toxic metabolites. Paradoxically, oxygen inflow during reperfusion results in production of reactive oxygen species (ROS), widespread activation of inflammatory pathways and cell death, a process termed
ADVANTAGES OF MACHINE PERFUSION
Although intricate in execution, the concept underlying machine perfusion is quite simple. Constant circulation supports endothelial function and washes out metabolic waste. Supplementation of oxygen, nutrients, metabolic substrates and other 'additives' allows the liver to maintain physiologic metabolic function, recover the energy deficit incurred during the procurement and early preservation period, and institute normal repair and regenerative pathways. In other words, machine perfusion is a platform for the graft to 'live' outside the body. Machine perfusion has several advantages compared with SCS, including:
(1) Prevents cold ischemia-related organ damage (2) 'Reconditions' marginal allografts (3) Allows viability assessment to detect poorly functioning organs before liver transplantation (4) Prolongs preservation period to improve organ utilization and surgical logistics (5) Serves as a platform for targeted therapeutic interventions Machine perfusion is classified by perfusion temperature as normothermic (35-38 8C) , hypothermic (4-10 8C) or subnormothermic (20-30 8C). The reader is directed to recent reviews for description of the key technical components [10, 11] .
NORMOTHERMIC MACHINE PERFUSION
Normothermic machine perfusion (NMP) aims to simulate a near-physiologic environment, which maintains normal metabolic function and avoids cold ischemic injury. Viability is assessed by measurement of hemodynamic performance (vascular flow and resistance), biochemical parameters and synthetic function [12, 13] . NMP is technically challenging, requiring dual perfusion of the hepatic artery and portal vein, an oxygen carrier perfusate and nutritional supplementation to support the fully functional liver [14, 15] .
NMP is still investigational in the clinical setting. The Oxford group reported the first phase 1 clinical trial, demonstrating that NMP with the transportable OrganOx Metra device is safe and feasible in both donation after brain death (DBD) and DCD grafts [16 & ]. One minor technical issue was corrected during ground transport, however, no device failures occurred and all livers were successfully transplanted. Notably, the NMP cohort had a significantly lower peak in AST and lower incidence of EAD after transplantation compared with matched controls and no recipient developed ischemic cholangiopathy [16 & ]. This study also demonstrated viability assessment during NMP, via measurement of hemodynamics, metabolic and synthetic function during perfusion.
Two Clinical trials demonstrate safety of machine perfusion and confirm improved outcomes compared with SCS.
Ongoing and future research will further expand the role of machine perfusion as a platform for graft intervention. Table 2 for details of the additional ongoing RCTs and pilot trials.
HYPOTHERMIC MACHINE PERFUSION
Hypothermic machine perfusion (HMP) restores mitochondrial function, reducing ROS release and inflammatory cascade activation upon reperfusion [22] . HMP has also been shown to improve hepatobiliary secretory function and preserve endothelial function in discarded ECD livers [23, 24] .
HMP is the least complex machine perfusion system. Perfusion can be performed via the portal vein alone or as dual perfusion. Active oxygenation has shown benefit in DCD and steatotic livers, but is not a strict requirement [25, 26 & ,27 28, 29] . In current practice, most centers will employ dual perfusion, active oxygenation (HOPE), or both (DHOPE; see Table 3 for details of completed HMP pilot studies). This versatility is facilitated by the minimal metabolic demands of the liver under hypothermic conditions. Additionally, HMP treatment is typically end-ischemic, avoiding need for device transportation or additional personnel/equipment. However, a distinct disadvantage of the near-dormant metabolism is the inability to perform meaningful viability assessment.
The largest HMP clinical trial, including 50 DCD grafts, has recently reported preliminary results including 5-year follow-up analysis. HMPperfused grafts achieved superior outcomes compared with nonperfused DCD grafts and comparable outcomes to DBD grafts [26 & ]. Multicenter RCTs are currently underway evaluating HMP compared with SCS for extended DBD and DCD grafts [30] (see Table 4 ).
SUBNORMOTHERMIC MACHINE PERFUSION
Subnormothermic machine perfusion (SMP) serves as a compromise between warm and cold perfusion. Although an oxygen carrier may be utilized, liver metabolism is sufficiently reduced such that adequate oxygenation can be achieved via diffusion alone into a crystalloid-based perfusate. Additionally, SMP-preserved livers retain partial functional capacity, demonstrated by bile production and lactate clearance during perfusion. To date, the experience in SMP has been limited to animal transplantation and discarded human liver perfusion models [31] [32] [33] [34] .
CONTROLLED OXYGENATED REWARMING
Controlled oxygenated rewarming (COR) is the most recent machine perfusion iteration, in which machine perfusion is initiated at hypothermic temperatures and gradually increased to subnormothermia [35] . COR avoids heat shock injury caused by abrupt temperature shifts. The slow increase in metabolism and functional restitution prepares the graft for additional reconditioning during SMP or prior to normothermic reperfusion [36] . COR with a normothermic final temperature (COR35) was recently compared with subnormothermic COR (COR20) in a rat liver model [37] . The COR groups demonstrated similar therapeutic benefit, however, the COR35 livers had more reliable bile production, which may enable reliable viability assessment [37] .
COR has recently been applied clinically, with the successful transplantation of six DBD grafts accepted under 'rescue allocation' criteria [38 & ]. The COR group demonstrated lower peak AST and INR compared with controls with 100% patient and graft survival at 6 months. The same group is currently conducting a pilot trial (CORAL Trial) comparing COR to SCS (see Tables 3 and 4) .
MACHINE PERFUSION OF MARGINAL ORGANS
The ex-vivo machine perfusion environment is unique in that the organ is both functional and isolated. Machine perfusion converts the preservation period from a race against the clock into an opportunity to apply targeted graft-improving interventions without systemic effect in the donor or recipient. In this regard, warm perfusion is ideal for manipulation of the functional liver. This concept will be discussed as it relates to DCD, steatotic and elderly grafts.
Donation after circulatory death
Of the 7500 liver transplants performed in the United States in 2016, only 6% were DCD [AOPO.org]. Of recovered DCD livers, 29% were The dawn of liver perfusion machines Detelich and Markmann discarded, compared with 6% of recovered DBD livers [AOPO.org]. Although striking, this still underestimates the discrepancy considering recovery is often not attempted in DCD donors. Improving utilization of DCD livers is clearly an important strategy to increase the donor pool. As mentioned, IRI underlies EAD and PNF in marginal organs. The obligatory warm ischemia of DCD recovery preconditions the liver, and especially cholangiocytes, for severe injury during SCS and reperfusion [15] . The biliary consequence is ischemic cholangiopathy, occurring in 20-40% of DCD grafts, compared with 5% in DBD grafts [39] . This complication carries high morbidity and mortality, routinely requiring multiple invasive procedures and up to 50% require retransplantation [10] .
Recent evidence shows that machine perfusion reconditions DCD allografts, effectively reversing the deleterious effects of ischemia. However, machine perfusion alone may not be sufficient for all grafts. Addition of targeted interventions during perfusion has been suggested to augment the protective effect against IRI. Various targeted anti-inflammatory, antioxidant, antiapoptosis and vasoactive pharmaceuticals have been added to storage solutions with the goal of modulating IRI, however, the experience in ex-vivo perfusion is limited [40] [41] [42] [43] .
Goldaracena et al. assessed the effect of an antiinflammatory cocktail (prostaglandin E1, acetylcysteine, sevoflurane and carbon monoxide) and decreased circuit temperature (33 8C) in a porcine transplantation model. Compared with controls perfused at 37 8C or SCS, livers receiving antiinflammatory treatment had reduced markers of inflammation, improved endothelial function and improved graft function [44 & ].
Defatting
Consequent to the increasing incidence of fatty liver disease, 40-60% of donor allografts have fatty infiltration [45] . The limit of acceptable donor steatosis has yet to be established. Grafts with mild macrosteatosis (<30%) are generally considered safe for transplantation; however, moderately (30-60%) or severely (>60%) macrosteatotic grafts are often declined because of increased risk of EAD, PNF and acute rejection postliver transplantation [45] [46] [47] [48] [49] [50] . Steatosis exacerbates IRI secondary to increased ROS generation, pro-inflammatory immune system activation, impaired mitochondrial ATP production and microcirculatory dysfunction, resulting in hepatocyte necrosis and graft failure upon reperfusion [46, 47] .
NMP and SMP have been investigated as alternative preservation methods of steatotic livers in animal models [51, 52] . Okamura et al. evaluated the effect of SMP on severely steatotic rat livers. SMPpreserved livers exhibited maintained microvascular integrity and sustained mitochondrial function, resulting in higher energy charge compared with cold-stored organs [53] .
Kron et al. [54 & ] evaluated end-ischemic HOPE of severely steatotic livers in a rat transplantation model. HOPE reduced inflammatory injury and subsequent fibrosis postliver transplantation, an effect that was dependent on oxygenation. However, HOPE had no impact on the amount of steatosis in the graft. The authors then analyzed the effect of HOPE in six steatotic human livers from their clinical trial, including five DCD. All livers demonstrated adequate early function as well as lower peak postliver transplantation ALT, decreased incidence of PNF (0 versus 25%), shorter ICU stay and improved 1-year patient survival (100 versus 42%) compared with SCS controls, a promising proof-of-concept for HOPE in fatty livers [54 & ].
Perfusion defatting seeks to augment the protective effect of perfusion by adding a pharmacologic 'defatting cocktail,' stimulating lipid metabolism [55] . Such treatment has been shown to significantly reduce lipid droplet burden, increase ATP production and lessen oxidative stress in cultured hepatatocytes [46] . Use of a defatting cocktail reduced intracellular lipid content by 50% during 3 h of NMP in steatotic rat livers [56] . Efficacy of defatting cocktails may require normothermia, as similar effect was not seen under subnormothermic conditions [55] .
Clinical experience of defatting is scarce. Banan et al. [57 & ] administered a defatting cocktail to two steatotic livers in an ex-vivo perfusion model, demonstrating a 10% reduction in one liver, although neither steatotic liver displayed increased markers of IRI. Considering that steatosis resolves quickly postliver transplantation, overcoming the initial risk of PNF/EAD may be key to improving viability and long-term survival [58, 59] .
Elderly
The functional capacity and physiologic reserve of the liver undergo normal decline with age, marked by volume loss, decreased blood flow, impaired regenerative capacity and atherosclerotic changes in the arterial vasculature [60] . Elderly donors also have more medical comorbidities. Concordantly, advanced donor age has been identified as an independent risk factor for EAD, graft loss and reduced recipient survival after liver transplantation, particularly in HCV-positive recipients [60, 61] . Despite the aging general population, use of elderly grafts is limited. With careful donor and recipient selection, some centers have found success with septuagenarian or even octogenarian donors [62, 63] . These results suggest that age may be a confounder and coexisting risk factors are at least partially responsible for the observed poor function [64] .
Machine perfusion serves two primary roles in the elderly. First is neutralizing the impact of other risk factors that predispose to IRI and subsequent dysfunction (such as prolonged CIT or steatosis). Secondly, viability assessment confirms the functionality and helps predict the effect of comorbid factors on transplant outcomes. Pezzati et al. [65] report a case of an octogenarian graft with severe atherosclerosis and poor initial flush that was reconditioned and assessed with NMP prior to successful transplantation. If machine perfusion can limit the CIT, mitigate steatosis and recondition the DCD graft, then a much larger pool of elderly donors would be acceptable for transplantation.
FUTURE DIRECTIONS
Ex-vivo organ perfusion technology is rapidly advancing. Progression from the experimental to the clinical realm has demonstrated early success, particularly for marginal livers. Attention is now turning toward employing the perfusion system as a platform for concurrent graft modification. Intervention during the ex-vivo period is highly advantageous to alter the liver phenotype prior to transplantation while avoiding systemic effects in the donor or recipient. We briefly introduced emerging therapies to reduce IRI and defat steatotic grafts, however, this just scratches the surface of conceivable interventions. Additional targets, such as antiviral medication for viral hepatitis, immune modulation for tolerance induction and gene therapy are under exploration [66, 67] . Novel drug delivery systems, such as nanoparticles, aim to augment therapeutic efficacy with precise control of drug delivery and release and may prove to be a key component of machine perfusion graft intervention [68] . Machine perfusion has also been utilized during radical ex-vivo hepatic surgery, such as during autotransplantation for end-stage alveolar echinococcosis or resection of large tumors with critical invasion of the retrohepatic vena cava [69, 70] . Continued research will solidify the use of machine perfusion as a tool for graft intervention in transplantation as well as facilitate treatment of hepatic disease in the nontransplantation setting.
CONCLUSION
The ever-increasing demand for liver transplantation has put suitable liver allografts at a premium and the use of marginal grafts represents a practical method for increasing the donor pool. Use of these grafts is dependent on the ability to recondition the graft and assess its viability. Recent clinical trials demonstrate that machine perfusion is capable of fulfilling both requirements. Continued investigation is necessary to determine optimal perfusion conditions, establish indications for machine perfusion and set guidelines for institutional implementation prior to becoming standard practice. Regardless, a new day in transplantation has arrived and the future of ex-vivo machine perfusion is bright.
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